{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:44:28Z","timestamp":1768013068862,"version":"3.49.0"},"reference-count":46,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>A systematic review of the impact of botulinum-A toxin as a therapeutic regimen for the management of adult migraine disorders is shown to that Botulinum-A toxin provides a more significant reduction in the number of headache episodes per month relative to placebo (MD: -0.61, 95% CI: -1.02 to -0.19). In subgroup analysis, botulinum-A toxin significantly reduced headache episodes per month relative to placebo for chronic migraine (MD: -1.68, 95% CI: -3.31 to -0.06), migraine (MD: -2.43, 95% CI: -4.08 to -0.77), and follow-up time in 16 weeks (MD: -2.19, 95% CI: -3.84 to -0.53). Statistical differences were not found in subgroup analyses of data relating to chronic migraine, episodic migraine, and other treatment course durations. An analysis of chronic and episodic migraine, botulinum-A toxin did not significantly differ from placebo in the proportion of patients achieving a fifty percent reduction in the number of headaches per month. In terms of patients\u2019 subjective reporting of headaches, botulinum toxin A conferred significant improvements when assessment questionnaires of migraine disability and migraine impact were analyzed. However, differences were not substantial with data from the 6-item headache impact test. This meta-analysis demonstrated that botulinum-A toxin as a therapeutic regimen improved the impact of chronic migraines after 16 weeks of therapy, although this was not the case for episodic migraine.<\/jats:p>","DOI":"10.31083\/j.jin.2020.01.1240","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T01:16:42Z","timestamp":1586308602000},"source":"Crossref","is-referenced-by-count":12,"title":["Impact of the botulinum-A toxin on prevention of adult migraine disorders"],"prefix":"10.31083","volume":"19","author":[{"given":"Bin","family":"Shen","sequence":"first","affiliation":[{"name":"Jiangsu Vocational College of Medicine, Yancheng, 224005, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"first","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, 430065, P. R. China"},{"name":"Institute of Chinese Medicine Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430061, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Agostoni, E. C. and Barbanti, P. (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. The Journal of Headache and Pain 20, 92.","DOI":"10.1186\/s10194-019-1038-4"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Anand, K. S., Prasad, A., Singh, M. M., Sharma, S. and Bala, K. (2006) Botulinum toxin type A in prophylactic treatment of migraine. American Journal of Therapeutics 13, 183-187.","DOI":"10.1097\/01.mjt.0000212705.79248.74"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B. and Diener, H. C. (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30, 793-803.","DOI":"10.1177\/0333102410364676"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Aurora, S. K., Gawel, M., Brandes, J. L., Pokta, S. and Vandenburgh, A. M. (2007) Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47, 486-499.","DOI":"10.1111\/j.1526-4610.2006.00624.x"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Barbanti, P. and Ferroni, P. (2017) Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. Journal of Pain Research 10, 2319-2329.","DOI":"10.2147\/JPR.S113614"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Barrientos, N. and Chana, P. (2003) Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. The Journal of Headache and Pain 4, 146-151.","DOI":"10.1007\/s10194-003-0049-2"},{"key":"ref7","unstructured":"Binder, W. (1998) A method for reduction of migraine headache pain. US Patent No. 5714468."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Bruloy, E., Sinna, R., Grolleau, J. L., Bout-Roumazeilles, A., Berard, E. and Chaput, B. (2019) Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plastic and Reconstructive Surgery 143, 239-250.","DOI":"10.1097\/PRS.0000000000005111"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Burstein, R., Zhang, X., Levy, D., Aoki, K. R. and Brin, M. F. (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34, 853-869.","DOI":"10.1177\/0333102414527648"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cady, R., Turner, I., Dexter, K., Beach, M. E., Cady, R. and Durham, P. (2014) An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine. Headache 54, 269-277.","DOI":"10.1111\/head.12250"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Clare, P., Claire, L., Caroline, R., William, J., Julie, E., Natalie, J., Carl, E. and Sinclair, A. (2019) Cochrane systematic review and metaanalysis of botulinum toxin for the prevention of migraine. BMJ Open 9, e027953.","DOI":"10.1136\/bmjopen-2018-027953"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Copas, J. and Shi, J. Q. (2000) Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1, 247-262.","DOI":"10.1093\/biostatistics\/1.3.247"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"de Tommaso, M., Ambrosini, A., Brighina, F., Coppola, G., Perrotta, A., Pierelli, F., Sandrini, G., Valeriani, M., Marinazzo, D., Stramaglia, S. and Schoenen, J. (2014) Altered processing of sensory stimuli in patients with migraine. Nature Reviews Neurology 10, 144-155.","DOI":"10.1038\/nrneurol.2014.14"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Deeks, J. J. (2002) Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 21, 1575-1600.","DOI":"10.1002\/sim.1188"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., Silberstein, S. D. and Brin, M. F. (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30, 804-814.","DOI":"10.1177\/0333102410364677"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ekkert, A., Noreikaite, K., Valiulis, V. and Ryliskiene, K. (2019) Migraine-linked characteristics of transcranial magnetic stimulation-induced phosphenes. Journal of Integrative Neuroscience 18, 463-466.","DOI":"10.31083\/j.jin.2019.04.1182"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Elkind, A. H., O'Carroll, P., Blumenfeld, A., DeGryse, R. and Dimitrova, R. (2006) A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. The Journal of Pain 7, 688-696.","DOI":"10.1016\/j.jpain.2006.03.002"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Evers, S., Vollmer-Haase, J., Schwaag, S., Rahmann, A., Husstedt, I. W. and Frese, A. (2004) Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia 24, 838-843.","DOI":"10.1111\/j.1468-2982.2004.00754.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Frampton, J. E. and Silberstein, S. (2018) OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs 78, 589-600.","DOI":"10.1007\/s40265-018-0894-6"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Freitag, F. G., Diamond, S., Diamond, M. and Urban, G. (2008) Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 48, 201-209.","DOI":"10.1111\/j.1526-4610.2007.00963.x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gazerani, P., Staahl, C., Drewes, A. M. and Arendt-Nielsen, L. (2006) The effects of Botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122, 315-325.","DOI":"10.1016\/j.pain.2006.04.014"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gooriah, R. and Ahmed, F. (2015) OnabotulinumtoxinA for chronic migraine: a critical appraisal. Therapeutics and Clinical Risk Management 11, 1003-1013.","DOI":"10.2147\/TCRM.S76964"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N. J., Clarke, C. E. and Sinclair, A. J. (2019) Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 9, e027953.","DOI":"10.1136\/bmjopen-2018-027953"},{"key":"ref24","unstructured":"Higgins, J. P. T. and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions. London, CA: Cochrane."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Higgins, J. P. and Thompson, S. G. (2002) Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21, 1539-1558.","DOI":"10.1002\/sim.1186"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hou, M., Xie, J. F., Kong, X. P., Zhang, Y., Shao, Y. F., Wang, C., Ren, W. T., Cui, G. F., Xin, L. and Hou, Y. P. (2015) Acupoint injection of onabotulinumtoxin A for migraines. Toxins 7, 4442-4454.","DOI":"10.3390\/toxins7114442"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Jackson, J. L., Kuriyama, A. and Hayashino, Y. (2012) Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. The Journal of the American Medical Association 307, 1736-1745.","DOI":"10.1001\/jama.2012.505"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Lauretti, G., Rosa, C., Kitayama, A. and Lopes, B. (2014) Comparison of botox \u00ae or prosigne \u00ae and facial nerve blockade as adjuvant in chronic migraine . Journal of Biomedical Science and Engineering 7, 446-452.","DOI":"10.4236\/jbise.2014.78047"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Linde, M., Gustavsson, A., Stovner, L. J., Steiner, T. J., Barre, J., Katsarava, Z., Lainez, J. M., Lampl, C., Lanteri-Minet, M., Rastenyte, D., Ruiz de la Torre, E., Tassorelliz, C. and Andree, C. (2012) The cost of headachedisorders in Europe: the Eurolight project. European Journal of Neurology 19, 703-711.","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Linde, M., Mulleners, W. M., Chronicle, E. P. and McCrory, D. C. (2013a) Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews, CD010608.","DOI":"10.1002\/14651858.CD010608"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Linde, M., Mulleners, W. M., Chronicle, E. P. and McCrory, D. C. (2013b) Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews, CD010609.","DOI":"10.1002\/14651858.CD010609"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J. and Varon, S. F. (2016) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 36, 899-908.","DOI":"10.1177\/0333102416652092"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Matharu, M., Halker, R., Pozo-Rosich, P., DeGryse, R., Manack, Adams. A. and Aurora, S. K. (2017) The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The Journal of Headache and Pain 18, 78.","DOI":"10.1186\/s10194-017-0784-4"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Mazzocchio, R. and Caleo, M. (2015) More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21, 44-61.","DOI":"10.1177\/1073858414524633"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Negro, A., Curto, M., Lionetto, L. and Martelletti, P. (2015) A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. The Journal of Headache and Pain 17, 1.","DOI":"10.1186\/s10194-016-0591-3"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Pedraza, M. I., de la Cruz, C., Ruiz, M., Lopez-Mesonero, L., Martinez, E., de Lera, M. and Guerrero, A. L. (2015) OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus 4, 176.","DOI":"10.1186\/s40064-015-0957-z"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ranoux, D., Attal, N., Morain, F. and Bouhassira, D. (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Annals of Neurology 64, 274-283.","DOI":"10.1002\/ana.21427"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Relja, M., Poole, A. C., Schoenen, J., Pascual, J., Lei, X. and Thompson, C. (2007) A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27, 492-503.","DOI":"10.1111\/j.1468-2982.2007.01315.x"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Sandrini, G., Perrotta, A., Tassorelli, C., Torelli, P., Brighina, F., Sances, G. and Nappi, G. (2011) Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. The Journal of Headache and Pain 12, 427-433.","DOI":"10.1007\/s10194-011-0339-z"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Saper, J. R., Mathew, N. T., Loder, E. W., DeGryse, R. and VanDenburgh, A. M. (2007) A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Medicine 8, 478-485.","DOI":"10.1111\/j.1526-4637.2006.00168.x"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sarchielli, P., Granella, F., Prudenzano, M. P., Pini, L. A., Guidetti, V., Bono, G., Pinessi, L., Alessandri, M., Antonaci, F., Fanciullacci, M., Ferrari, A., Guazzelli, M., Nappi, G., Sances, G., Sandrini, G., Savi, L., Tassorelli, C. and Zanchin, G. (2012) Italian guidelines for primary headaches: 2012 revised version. The Journal of Headache and Pain 13 Suppl 2, S31-S70.","DOI":"10.1007\/s10194-012-0437-6"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Silberstein, S., Mathew, N., Saper, J. and Jenkins, S. (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40, 445-450.","DOI":"10.1046\/j.1526-4610.2000.00066.x"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 44, 167-193.","DOI":"10.1146\/annurev.pharmtox.44.101802.121554"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Teunis, T. (2019) Botulinum toxin versus placebo: a meta- analysis of prophylactic treatment for migraine. Plastic and Reconstructive Surgery 143, 239-250.","DOI":"10.1097\/PRS.0000000000005111"},{"key":"ref45","unstructured":"Vo, A. H., Satori, R., Jabbari, B., Green, J., Killgore, W. D., Labutta, R. and Campbell, W. W. (2007) Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Aerospace Medicine and Human Performance 78, B113-B118."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Vos, T., Allen, C., Arora, M., Barber, R. B., Bhutta, V., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coggeshall, M., Cornaby, L., et al. (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545-1602.","DOI":"10.1016\/S0140-6736(16)31678-6"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/19\/1\/10.31083\/j.jin.2020.01.1240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:19:24Z","timestamp":1732720764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/19\/1\/10.31083\/j.jin.2020.01.1240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["1757-448X-19-1-201"],"URL":"https:\/\/doi.org\/10.31083\/j.jin.2020.01.1240","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"article-number":"201"}}